Investing.com’s Fair Value models demonstrated their predictive power once again, as evidenced by the successful identification of Embecta Corp.’s (NASDAQ:EMBC) overvaluation in December 2024. The ...

Embecta (Nasdaq:EMBC) today revealed its phased plan to create value and shift priorities toward broader medical applications. The pure-play diabetes technology company has endured ups and downs since ...

Embecta Corp. (EMBC) shares tumbled to a 52-week low of $10.26, reflecting a challenging period for the medical device company. The stock has experienced a steep decline of over 47% in the past six ...

On Thursday, BofA Securities analyst Travis Steed reduced the price target on Embecta shares (NASDAQ: EMBC) to $18.00, down from the previous $20.00, while maintaining an Underperform rating on the ...